These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 32737087)

  • 1. Open-label, multicentre, single-arm trial of monthly injections of depot buprenorphine in people with opioid dependence: protocol for the CoLAB study.
    Larance B; Byrne M; Lintzeris N; Nielsen S; Grebely J; Degenhardt L; Shahbazi J; Shanahan M; Lancaster K; Dore G; Ali R; Farrell M;
    BMJ Open; 2020 Jul; 10(7):e034389. PubMed ID: 32737087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 96-week retention in treatment with extended-release subcutaneous buprenorphine depot injections among people with opioid dependence: Extended follow-up after a single-arm trial.
    Farrell M; Shahbazi J; Chambers M; Byrne M; Gholami J; Zahra E; Grebely J; Lintzeris N; Larance B; Ali R; Nielsen S; Dunlop A; Dore GJ; McDonough M; Montebello M; Weiss R; Rodgers C; Cook J; Degenhardt L;
    Int J Drug Policy; 2024 May; 127():104390. PubMed ID: 38522175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injections in people with opioid dependence.
    Farrell M; Shahbazi J; Byrne M; Grebely J; Lintzeris N; Chambers M; Larance B; Ali R; Nielsen S; Dunlop A; Dore GJ; McDonough M; Montebello M; Nicholas T; Weiss R; Rodgers C; Cook J; Degenhardt L;
    Int J Drug Policy; 2022 Feb; 100():103492. PubMed ID: 34736130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Haight BR; Learned SM; Laffont CM; Fudala PJ; Zhao Y; Garofalo AS; Greenwald MK; Nadipelli VR; Ling W; Heidbreder C;
    Lancet; 2019 Feb; 393(10173):778-790. PubMed ID: 30792007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Experience and response to a randomised controlled trial of extended-release injectable buprenorphine versus sublingual tablet buprenorphine and oral liquid methadone for opioid use disorder: protocol for a mixed-methods evaluation.
    Lowry N; Cowden F; Day E; Gilvarry E; Johnstone S; Murray R; Kelleher M; Mitcheson L; Marsden J
    BMJ Open; 2022 Oct; 12(10):e067194. PubMed ID: 36270754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extended-release pharmacotherapy for opioid use disorder (EXPO): protocol for an open-label randomised controlled trial of the effectiveness and cost-effectiveness of injectable buprenorphine versus sublingual tablet buprenorphine and oral liquid methadone.
    Marsden J; Kelleher M; Hoare Z; Hughes D; Bisla J; Cape A; Cowden F; Day E; Dewhurst J; Evans R; Hearn A; Kelly J; Lowry N; McCusker M; Murphy C; Murray R; Myton T; Quarshie S; Scott G; Turner S; Vanderwaal R; Wareham A; Gilvarry E; Mitcheson L
    Trials; 2022 Aug; 23(1):697. PubMed ID: 35986418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Open-label, rapid initiation pilot study for extended-release buprenorphine subcutaneous injection.
    Hassman H; Strafford S; Shinde SN; Heath A; Boyett B; Dobbins RL
    Am J Drug Alcohol Abuse; 2023 Jan; 49(1):43-52. PubMed ID: 36001871
    [No Abstract]   [Full Text] [Related]  

  • 8. The switching process from buprenorphine sublingual tablets to the monthly buprenorphine subcutaneous depot injection in opioid dependent patients.
    Guillery SPE; Reiners S; Fahrner M; Enge S; Hellweg R; Kunte H; Kronenberg G
    Addict Biol; 2023 May; 28(5):e13275. PubMed ID: 37186443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient-Reported Outcomes of Treatment of Opioid Dependence With Weekly and Monthly Subcutaneous Depot vs Daily Sublingual Buprenorphine: A Randomized Clinical Trial.
    Lintzeris N; Dunlop AJ; Haber PS; Lubman DI; Graham R; Hutchinson S; Arunogiri S; Hayes V; Hjelmström P; Svedberg A; Peterson S; Tiberg F
    JAMA Netw Open; 2021 May; 4(5):e219041. PubMed ID: 33970256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can a new formulation of opiate agonist treatment alter stigma?: Place, time and things in the experience of extended-release buprenorphine depot.
    Treloar C; Lancaster K; Gendera S; Rhodes T; Shahbazi J; Byrne M; Degenhardt L; Farrell M
    Int J Drug Policy; 2022 Sep; 107():103788. PubMed ID: 35816790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of an injectable monthly extended-release buprenorphine program in a low-barrier specialty addiction medicine clinic.
    Heil J; Salzman M; Hunter K; Baston KE; Milburn C; Schmidt R; Haroz R; Ganetsky VS
    J Subst Use Addict Treat; 2024 Jan; 156():209183. PubMed ID: 37879433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medication treatment for opioid use disorder in expectant mothers (MOMs): Design considerations for a pragmatic randomized trial comparing extended-release and daily buprenorphine formulations.
    Winhusen T; Lofwall M; Jones HE; Wilder C; Lindblad R; Schiff DM; Wexelblatt S; Merhar S; Murphy SM; Greenfield SF; Terplan M; Wachman EM; Kropp F; Theobald J; Lewis M; Matthews AG; Guille C; Silverstein M; Rosa C
    Contemp Clin Trials; 2020 Jun; 93():106014. PubMed ID: 32353544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient-centered Outcomes in Participants of a Buprenorphine Monthly Depot (BUP-XR) Double-blind, Placebo-controlled, Multicenter, Phase 3 Study.
    Ling W; Nadipelli VR; Solem CT; Ronquest NA; Yeh YC; Learned SM; Mehra V; Heidbreder C
    J Addict Med; 2019; 13(6):442-449. PubMed ID: 30844878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world outcomes with extended-release buprenorphine (XR-BUP) in a low threshold bridge clinic: A retrospective case series.
    Peckham AM; Kehoe LG; Gray JR; Wakeman SE
    J Subst Abuse Treat; 2021 Jul; 126():108316. PubMed ID: 34116808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Open-label investigation of rapid initiation of extended-release buprenorphine in patients using fentanyl and fentanyl analogs.
    Mariani JJ; Dobbins RL; Heath A; Gray F; Hassman H
    Am J Addict; 2024 Jan; 33(1):8-14. PubMed ID: 37936553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subcutaneous Extended-release Buprenorphine Depot Misdiagnosed as an Abscess Resulting in Incision and Drainage and Disruption of Opioid Use Disorder Treatment.
    Gray JR; Kehoe LG; Peckham AM; Wakeman SE
    J Addict Med; 2023 Mar-Apr 01; 17(2):227-229. PubMed ID: 36074787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Case Report: Rapid Micro-Induction of Buprenorphine/Naloxone to Administer Buprenorphine Extended-Release in an Adolescent With Severe Opioid Use Disorder.
    Azar P; Wong JSH; Jassemi S; Moore E; Vo DX; Nikoo M; Young S
    Am J Addict; 2020 Nov; 29(6):531-535. PubMed ID: 32346944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population Pharmacokinetics of a Monthly Buprenorphine Depot Injection for the Treatment of Opioid Use Disorder: A Combined Analysis of Phase II and Phase III Trials.
    Jones AK; Ngaimisi E; Gopalakrishnan M; Young MA; Laffont CM
    Clin Pharmacokinet; 2021 Apr; 60(4):527-540. PubMed ID: 33135125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retention in care for persons with opioid use disorder transitioning from sublingual to injectable buprenorphine.
    Stein MD; VanNoppen D; Herman DS; Anderson BJ; Conti M; Bailey GL
    J Subst Abuse Treat; 2022 May; 136():108661. PubMed ID: 34801283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Superiority and cost-effectiveness of monthly extended-release buprenorphine versus daily standard of care medication: a pragmatic, parallel-group, open-label, multicentre, randomised, controlled, phase 3 trial.
    Marsden J; Kelleher M; Gilvarry E; Mitcheson L; Bisla J; Cape A; Cowden F; Day E; Dewhurst J; Evans R; Hardy W; Hearn A; Kelly J; Lowry N; McCusker M; Murphy C; Murray R; Myton T; Quarshie S; Vanderwaal R; Wareham A; Hughes D; Hoare Z
    EClinicalMedicine; 2023 Dec; 66():102311. PubMed ID: 38045803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.